Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Thursday, March 28, 2024 · 699,478,637 Articles · 3+ Million Readers

CHF Solutions to Exhibit at Heart Failure 2018 in Vienna, Austria

EDEN PRAIRIE, Minn., May 17, 2018 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq:CHFS), today announces that it will be exhibiting at the Heart Failure Meeting from May 26-29, 2018 in Vienna, Austria. This annual congress is organized by the Heart Failure Association of the European Society of Cardiology and draws approximately 6,000 medical professionals, primarily from Europe, who are focused on improving the care of heart failure patients.  Physicians from Asia, and North and South America will also be in attendance.   

The company will be featuring the Aquadex FlexFlow System and highlighting the clinically proven benefits of the therapy.  CHF Solutions’ can be found in Booth #I100 on the exhibition floor at Messe Wein throughout the conference. 

“Heart Failure 2018 is a strategic addition to our conference calendar as we expand awareness in Europe and continue to inform practitioners on the clinical solution and economic value of our therapy.   We look forward to connecting with the Cardiology community at the 2018 congress and further educating on the benefits of our Aquadex FlexFlow System,” said John Erb, chief executive officer of CHF Solutions. 

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

CONTACTS:

INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

Primary Logo

Powered by EIN News
Distribution channels: Conferences & Trade Fairs, Retail


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release